Search Results for: ?????? ???????? Human Design ?????????? ??????? ??????? ? ??????????? ?????????????? ??????????? ????????, ??? ??????????? ???? ?????? ?????????? http://instagram.com/batmanapollo – Page 5

The House Ways and Means Committee will vote tomorrow, May 8, on legislation that will include a so-called “delinking” policy in Medicare. To be clear, the “delinking” policy proposal is backed by Big Pharma because it will significantly boost profits.

The vast majority of employers and public health programs voluntarily work with pharmacy benefit companies to manage pharmacy benefits. So, what happens when a health plan doesn’t use a pharmacy benefit company? A recent Department of Labor (DOL) Office of the

As independent pharmacies conduct a “Fly-In” in Washington D.C this week, they will undoubtedly double-down on support for policies targeting pharmacy benefit companies that would have profound negative consequences for employers, taxpayers, and patients. It’s important for lawmakers to consider

As Congress returns to Washington, Ike Brannon, senior fellow at the Jack Kemp Foundation, explains how state and federal efforts to undermine the role of pharmacy benefit managers (PBMs) would do nothing to reduce drug costs in a new op-ed

The pharmacy benefit company market is competitive and diverse, with more than 70 full-service PBMs of varying size operating across the country. These companies differentiate themselves through the services, contract terms, and products they offer. Across this competitive industry is a common mission

In case you missed it, former U.S. Senator Pat Toomey (R-PA) explains how the Biden Administration’s recent push targeting pharmacy benefit companies is a deflecting tactic that will only result in increased prescription drug costs in a recent op-ed published